Peter Schmid

机构：Queen Mary University of London, Barts Cancer Institute · ORCID：0000-0001-9817-5228

发表论文 36 篇 · 总被引 1176 次 · h-index 7

代表论文

• Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (2024 · New England Journal of Medicine · 被引 551)
• Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial (2023 · The Lancet · 被引 476)
• Neoadjuvant pembrolizumab plus chemotherapy/adjuvant pembrolizumab for early-stage triple-negative breast cancer: quality-of-life results from the randomized KEYNOTE-522 study (2024 · JNCI Journal of the National Cancer Institute · 被引 42)
• Abstract GS1-11: Sacituzumab Govitecan (SG) vs Treatment of Physician’s Choice (TPC): Efficacy by Trop-2 Expression in the TROPiCS-02 Study of Patients (Pts) With HR+/HER2– Metastatic Breast Cancer (mBC) (2023 · Cancer Research · 被引 24)
• Abstract LB1-07: Exploratory Biomarker Analysis of the Phase 3 KEYNOTE-522 Study of Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for Early-Stage TNBC (2025 · Clinical Cancer Research · 被引 13)
• Abstract LBO1-01: Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer: Updated event-free survival results from the phase 3 KEYNOTE-522 study (2024 · Cancer Research · 被引 13)